Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.70 |
| ▸ | PGR | P06401 | 4/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | NR3C1 | P04150 | 10/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 2/20 | 0.64 |
| ▸ | TNF | P01375 | 2/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | IL6 | P05231 | 1/20 | 0.64 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.64 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.64 |
| ▸ | GLUL | P15104 | 1/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.64 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | IKBKB | O14920 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186333 | 1.00 | HIF1A (0.70) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL13692238 | 1.00 | HIF1A (0.70) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL29528606 | 0.94 | PGR (0.70) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL13655947 | 0.92 | HIF1A (0.70) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL13655915 | 0.92 | HIF1A (0.67) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL13692183 | 0.90 | PGR (0.78) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL13692244 | 0.90 | HIF1A (0.58) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL4091992 | 0.90 | HIF1A (0.58) | HIF1APGRLMNANR3C1CYP3A4 | |
| Hydrochloric Acid SCHEMBL5972770 | 0.90 | HIF1A (0.58) | HIF1APGRLMNANR3C1CYP3A4 | |
| SCHEMBL13694213 | 0.89 | HIF1A (0.71) | HIF1APGRLMNANR3C1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119792236-A | Functionalized bionic nano-particles targeting synovial macrophages and application thereof | 安徽理工大学 | 2025-04-11 | — | — | CN | claimed |
| EP-3946461-B1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | UNIV BRITISH COLUMBIA (CA) | 2025-01-15 | — | — | EP | claimed |
| EP-3946461-A1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | The University of British Columbia (CA) | 2022-02-09 | — | — | EP | claimed |
| CN-119792236-A | Functionalized bionic nano-particles targeting synovial macrophages and application thereof | 安徽理工大学 | 2025-04-11 | — | — | CN | disclosed |
| CN-119792236-A | Functionalized bionic nano-particles targeting synovial macrophages and application thereof | 安徽理工大学 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025072521-A1 | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID-MEDIATED DISEASES | SPARROW PHARMACEUTICALS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119630422-A | Methods of treating giant cell arteritis using interleukin-17 (IL-17) antagonists | 诺华股份有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-11491232-B2 | Lactuloside compounds and preparation and use thereof | Fruithy Holdings Limited (CN) | 2022-11-08 | — | — | US | disclosed |
| EP-3946461-A1 | XYLOGLUCAN-CONTAINING PRODRUGS AND METHODS OF MANUFACTURE AND USE THEREOF | The University of British Columbia (CA) | 2022-02-09 | — | — | EP | disclosed |
| US-20090264394-A1 | NITROOXY DERIVATIVES OF GLUCOCORTICOIDS | NICOX S.A. (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2002094942-A1 | METHOD OF PURIFYING POLYCYCLIC DYES | OPTIVA, INC. (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491232-B2 | Lactuloside compounds and preparation and use thereof | SI, VIP, LCT | HIF1A 1414/4885PGR 3335/4885LMNA 863/4885 |
| US-20090264394-A1 | NITROOXY DERIVATIVES OF GLUCOCORTICOIDS | NR3C1, NR3C2, NR5A1 | HIF1A 3438/4885PGR 161/4885LMNA 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.